Hans Minderman
Impact in
- Oncology top 2%
- Drug Transport and Resistance Mechanisms
- Immunology top 5%
- Immune cells in cancer
- Immunotherapy and Immune Responses
Papers in
- Oncology 51
- Drug Transport and Resistance Mechanisms 21
- Lung Cancer Research Studies 8
- Cancer Immunotherapy and Biomarkers 8
-
- Cancer therapeutics and mechanisms 15
- Extracellular vesicles in disease 7
- Co-authors
- Kieran L. O’Loughlin (29 shared papers)Maria R. Baer (20 shared papers)Orla Maguire (24 shared papers)Jonah Riddell (1 shared paper)Sandra O. Gollnick (1 shared paper)William R. Greco (8 shared papers)Xiangyang Wang (1 shared paper)Paul K. Wallace (13 shared papers)
- Journals
- Blood (9 papers)Cancer Chemotherapy and Pharmacology (5 papers)Cytometry Part A (4 papers)Cancer Research (4 papers)Journal of Clinical Oncology (4 papers)
- Partner nations
- United StatesNetherlandsGermany
In The Last Decade
Hans Minderman
91 papers receiving 3.4k citations
Peers
Comparison fields: 5 of 118
- Oncology 1.4k
- Immunology 708
- Hematology 368
- Cancer Research 416
- Molecular Biology 1.6k
Countries citing papers authored by Hans Minderman
This map shows the geographic impact of Hans Minderman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Minderman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Minderman more than expected).
Fields of papers citing papers by Hans Minderman
This network shows the impact of papers produced by Hans Minderman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Minderman. The network helps show where Hans Minderman may publish in the future.
Co-authors
The 25 scholars most cited alongside Hans Minderman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 96 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2002 | 292 | |
| 2 | 2005 | 209 | |
| 3 | 2009 | 186 | |
| 4 | 2010 | 157 | |
| 5 | 2018 | 154 | |
| 6 | 2004 | 146 | |
| 7 | 2019 | 141 | |
| 8 | 2020 | 107 | |
| 9 | 2011 | 106 | |
| 10 | Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. | 2003 | 105 |
| 11 | 2016 | 99 | |
| 12 | 2011 | 81 | |
| 13 | 2014 | 75 | |
| 14 | 2002 | 74 | |
| 15 | 2015 | 73 | |
| 16 | 2006 | 65 | |
| 17 | 2006 | 63 | |
| 18 | 2018 | 61 | |
| 19 | 2004 | 59 | |
| 20 | 1996 | 59 |
About Hans Minderman
Hans Minderman is a scholar working on Oncology, Molecular Biology, Immunology, Hematology and Cancer Research, having authored 96 papers that have together received 3.5k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (21 papers), Cancer therapeutics and mechanisms (15 papers), Acute Myeloid Leukemia Research (10 papers), Lung Cancer Research Studies (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), Extracellular vesicles in disease (7 papers), Immunotherapy and Immune Responses (6 papers) and HIV/AIDS drug development and treatment (6 papers). The work is most often cited by research in Oncology (1.4k citations), Immunology (708 citations), Hematology (368 citations), Cancer Research (416 citations) and Molecular Biology (1.6k citations). Hans Minderman has collaborated with scholars based in United States, Netherlands and Germany. Frequent co-authors include Kieran L. O’Loughlin, Maria R. Baer, Orla Maguire, Jonah Riddell, Sandra O. Gollnick, William R. Greco, Xiangyang Wang, Paul K. Wallace, Lakshmi Pendyala and Cheryl Allen. Their work appears in journals such as Blood, Cancer Chemotherapy and Pharmacology, Cytometry Part A, Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.